Experience With Carbon Ion Radiotherapy for WHO Grade 2 Diffuse Astrocytomas
Experience With Carbon Ion Radiotherapy for WHO Grade 2 Diffuse Astrocytomas
复制标题
DOI：
10.1016/j.ijrobp.2011.06.1952
复制
发表时间：
2012-05-01
影响因子：
7
通讯作者：
Takakura, Kintomo
中科院分区：
文献类型：
--
作者：
Hasegawa, Azusa;Mizoe, Jun-Etsu;Takakura, Kintomo
目的：评价碳离子放射治疗成人弥漫性星形细胞瘤的疗效。方法与材料：1994年10月至2002年2月，14例符合碳离子放疗条件的弥漫性星形细胞瘤患者入组I/II期临床试验。碳离子放射治疗分24次，持续6周。仔细监测正常组织的发病率，并将碳离子剂量从50.4 Gy当量（GyE）增加到55.2 Gy当量。根据碳离子剂量将患者分为两组：低剂量组，2例患者接受46.2 GyE照射，7例患者接受50.4 GyE照射；高剂量组，5例患者接受55.2 GyE照射。结果：毒性在可接受范围内，没有患者发生3级或更高级别的急性或晚期反应。低剂量组的中位无进展生存期（PFS）为18个月，高剂量组为91个月（p = 0.0030）。低剂量组的中位总生存期（OS）为28个月，高剂量组未达到（p = 0.0208）。结论：与低剂量组相比，高剂量组患者的PFS和OS率均有显著改善，两组毒性均可接受。(C) 2012爱思唯尔公司
Purpose: To assess outcomes of carbon ion radiotherapy for diffuse astrocytomas in adults.Methods and Materials: Between October 1994 and February 2002, 14 patients with diffuse astrocytoma, identified as eligible for carbon ion radiotherapy, were enrolled in a phase I/II clinical trial. Carbon ion radiotherapy was administered in 24 fractions over 6 weeks. The normal tissue morbidity was monitored carefully, and the carbon ion dose was escalated from 50.4 Gy equivalent (GyE) to 55.2 GyE. Patients were divided into two groups according to their carbon ion doses: a low-dose group in which 2 patients were irradiated with 46.2 GyE and 7 patients were irradiated with 50.4 GyE, and a high-dose group in which 5 patients were irradiated with 55.2 GyE.Results: Toxicities were within acceptable limits, and none of the patients developed Grade 3 or higher acute or late reactions. The median progression-free survival (PFS) time was 18 months for the low-dose group and 91 months for the high-dose group (p = 0.0030). The median overall survival (OS) time was 28 months for the low-dose group and not reached for the high-dose group (p = 0.0208).Conclusion: High-dose group patients showed significant improvement in PFS and OS rates compared to those in the low-dose group, and both dose groups showed acceptable toxicity. (C) 2012 Elsevier Inc.